On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)

American Heart Journal

Volumn 182, Issue , 2016, Pages 89-96

  Blazing, Michael A ^a   Giugliano, Robert P ^b   de Lemos, James A ^c   Cannon, Christopher P ^b   Tonkin, Andrew ^d   Ballantyne, Christie M ^e   Lewis, Basil S ^f   Musliner, Thomas A ^g   Tershakovec, Andrew M ^g   Lokhnygina, Yuliya ^a   White, Jennifer A ^a   Reist, Craig ^a   McCagg, Amy ^b   Braunwald, Eugene ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MONASH UNIVERSITY   (Australia)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f CARMEL MEDICAL CENTER   (Israel)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; EZETIMIBE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG MONITORING; DRUG POTENTIATION; MIDDLE AGED; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ACUTE CORONARY SYNDROME; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; HUMANS; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84991727507     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.09.004     Document Type: Article

References (15)

1. 1. Morrone, D., Weintraub, W.S., Toth, P.P., et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 223 (2012), 251–261.
2. 2. Kastelein, J.J., Akdim, F., Stroes, E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008), 1431–1443.
3. 3. Villines, T.C., Stanek, E.J., Devine, P.J., et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55 (2010), 2721–2726.
4. 4. Rossebø, A.B., Pedersen, T.R., Boman, K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008), 1343–1356.
5. 5. Cannon, C.P., Giugliano, R.P., Blazing, M.A., et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 156 (2008), 826–832.
6. 6. Blazing, M.A., Giugliano, R.P., Cannon, C.P., et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 168 (2014), 205–212.
7. 7. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
8. 8. U.S. Food and Drug Administration, FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury., 2011 Available at: http://www.fda.gov/drugs/drugsafety/ucm256581.htm [Accessed December 13, 2013].
9. 9. Giugliano, R.P., Newby, L.K., Harrington, R.A., et al. The early glycoprotein IIb/IIIa inhibition in non–ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—study design and rationale. Am Heart J 149 (2005), 994–1002.
10. 10. ICH Harmonised Tripartite Guideline, Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 18 (1999), 1905–1942.
11. 11. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
12. 12. Cannon, C.P., Steinberg, B.A., Murphy, S.A., et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006), 438–445.
13. 13. Nagelkerke, N., Fidler, V., Bernsen, R., et al. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med 19 (2000), 1849–1864.
14. 14. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 378 (2011), 2013–2020.
15. 15. Pandit, A.K., Kumar, P., Kumar, A., et al. High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurol Scand, 2015.